# Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

> **NCT06849921** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
- Hematologic Disease

## Interventions

- **DRUG:** Cellular Therapy

## Key facts

- **NCT ID:** NCT06849921
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849921, "Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06849921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*